BOSTON and TEL AVIV, Israel, March 30, 2021 /PRNewswire/ — Aulos Bioscience, a biotechnology company developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, announced today the appointment of Mace Rothenberg, M.D., to the company’s board of directors.
Read more here.
